Regeneron’s shares have faced challenges, but the company is rebounding. Competition for Eylea led to sales declines, but the high-dose formulation is now on the market with a better dosing schedule. FDA approval for macular edema enhances its competitive edge against Vabysmo, compensating for biosimilar competition.
Regeneron’s pipeline includes cemdisiran, a promising candidate for generalized myasthenia gravis, with plans for regulatory submissions next year. Trevogrumab for maintaining muscle mass and a gene therapy for hearing loss are also in development. These innovative therapies should strengthen the company’s product lineup and financial performance.
Despite recent setbacks, Regeneron’s shares have potential upside. New product approvals and a strong pipeline are boosting growth prospects. Considerations to buy the stock go beyond what’s discussed, highlighting the company’s resilience and promising outlook for investors.

Read more at Yahoo Finance: 2 Reasons to Buy Regeneron Stock Like There’s No Tomorrow